-
EOFlow Initiates Eco-Friendly Disposal Campaign for EOPatch in Korea Embracing and Integrating Environmental, Social, and Governance (ESG)
▶EOFlow will collect, process, and dispose of used EOPatch pumps in an environmentally safe manner ▶EOFlow will set up an Incentive Program for this Campaign EOFlow Co., Ltd. (KOSDAQ: 294090) (EOFlow or the Company), a provider of wearable drug delivery solutions, announced today that the Company is initiating an environmentally friendly disposal campaign to minimize the impact of used EOPatch pumps on the environment. As there are no environmental regulations or guidelines for proper disposal of used medical devices in Korea, used patc...Nov. 09. 2021 -
EOFlow to Raise 100 Billion Korean Won and Offer Stock Split Capital Raised Will Be Used For Global Market Expansion
▶ 100 billion Won to be raised with new common stock offering, to be followed by a 2:1 stock split EOFlow Co., Ltd. (KOSDAQ: 294090) (EOFlow or the Company), a provider of wearable drug delivery solutions, has announced today that the Company will raise some 100 billion Won with new common stock offering, after which it will do a 2:1 stock split. The Company will make a new public offering of its common stocks. The company will issue up to 3,000,000 shares of common stocks, representing 25.99% of the current total number of issued shares. The...Oct. 28. 2021 -
EOFlow and Sinocare Establish a Joint Venture Company
▶ Sinocare is China’s Largest Diabetes Management Instrument Manufacturer ▶ Joint venture company to launch a full-scale effort for clinical study to obtain regulatory approval for EOPatch manufacturing and distribution in China ▶ High growth expected from EOPatch business in China where world’s largest diabetes population live EOFlow Co., Ltd. (KOSDAQ: 294090) (EOFlow or the Company), a provider of wearable drug delivery solutions, has announced today that the Company will establish a joint venture company “SINOFLOW Co., Ltd...Oct. 27. 2021 -
EOFlow Begins Clinical Study of its Wearable Insulin Pump “EOPatch” on People With Type 2 diabetes in Korea
▶ This clinical study involves ten leading university hospitals and up to one hundred and thirty-six people with Type 2 diabetes. It is Korea’s largest ever clinical study employing insulin pumps. ▶ This pioneering study aims to demonstrate and validate efficacy of EOPatch for Type 2 diabetes therapy. EOFlow Co., Ltd. (KOSDAQ: 294090) (EOFlow or the Company), a provider of wearable drug delivery solutions, has announced today that the Company completed enrollment of first patient in a clinical study on type 2 diabetes for its wearable in...Oct. 14. 2021 -
EOFlow Completes its First Shipment to Europe
▶ EOFlow’s European exclusive distributing partner Menarini to showcase the EOPatch at EASD 2021 EOFlow Co., Ltd. (KOSDAQ: 294090) (EOFlow or the Company), a provider of wearable drug delivery solutions, has made its first shipment to Europe today. After launching the wearable insulin pump in Korea this March and obtaining the CE certification in May, EOFlow is now expanding its reach to Europe, starting with the first shipment completed on September 30. EOFlow officially launched its EOPatch, Korea’s first (and the w...Sep. 30. 2021 -
Meeting with Type 1 Diabetes Community - Again
From time to time, EOFLOW invites type 1 diabetic patients and their family members to come visit the company. Our first such meeting this year was held a few days ago, and we had our friends come from all over the country.Apr. 06. 2017 -
EOFLOW on TV
EOFLOW was featured in an exclusive 30-minute program from SBS-CNBC that covers promising start-up companies in Korea. You can view the program through the link provided below. Unfortunately, the program is in Korean only. http://sbscnbc.sbs.co.kr/read.jsp?pmArticleId=10000844774Feb. 08. 2017 -
EOFLOW closes its Series-B funding
EOFLOW is starting 2017 on a high note: the company successfully closed its Series-B round of funding. Three major venture capital firms invested some $5.5M in this round, including two large firms each managing over $1B funds. With the latest round of funding, combined with the company's current cash reserve and government grants, EOFLOW is well positioned for its first commercial product launch scheduled for later this year, as well as for execution of follow-on product development plans.Jan. 14. 2017 -
EOFLOW to present at the RESI Innovation Challenge
EOFLOW will present at the upcoming RESI Innovation Challenge to be held in San Francisco on January 10, 2017. There were more than 100 applicants to the event, and we're proud to be chosen as one of the 30 finalists. Check us out at: http://www.resiconference.com/innovation-challenge/Dec. 21. 2016 -
EOFLOW unveils its EOPatch design
EOFLOW today unveiled the final design of its first smart wearable insulin pump, EOPatch. The new design is much slimmer than the previously publicized design, with a dimension of 49mm x 32mm x 12.6mm. With the new footprint, EOPatch is the smallest known wearable insulin pump with adjustable basal and bolus delivery. The new design can be found on our website: www.eoflow.comSep. 10. 2016 -
EOPatch submitted for regulatory approval tests
After many years of development and refinements, EOFLOW's smart, disposable wearable insulin pump, EOPatch, has been officially submtted for verification and validation tests on 9/5/2016. We expect to be able to market the product in the global market in 2017.Sep. 07. 2016 -
EOPatch chosen as a next generation medical device 100
EOFLOW's smart disposable wearable insulin pump, EOPatch, has been chosen by the Korean government as one of the twenty devices chosen this year as a part of 'Next Generation Medical Device 100' which are meant to represent the most promising 100 new medical devices for the country. The selected companies will be supported by a group of experts and mentors to help expedite the regulatory approvals. This will ensure a more prompt debut of our product in 2017!Sep. 05. 2016 -
EOFLOW exhibits at EASD 2016, Munich
EOFLOW exhibits its commercial EOPatch wearable disposable insulin delivery product at the 52st EASD (European Association for the Study of Diabetes) Annual Meeting held in Munich, Germany, 9/12-16. EOFLOW's booth is Q.02.Aug. 29. 2016 -
EOFLOW exhibits at ADA 2016, New Orleans
EOFLOW exhibits the latest working sample of EOPatch wearable disposable insulin delivery product at a business partner’s booth at the 76th Scientific Sessions of ADA (American Diabetes Association) held in New Orleans, LA, 06/10-14.Jul. 12. 2016 -
EOFLOW is covered in another newspaper article
Aju News, a major economics newspaper in Korea, runs an article on EOFLOW and its EOPatch wearable disposable insulin pump. To read the Korean article, click the link below: http://www.ajunews.com/view/20160615013058993Jul. 12. 2016
Healthcare Innovation Park #H2202 Dolma-ro 172 Bundang-gu Seongnam-si Gyeonggi-do Republic of Korea
T (+82) 031-738-0200
F (+82) 031-738-0208
COPYRIGHT ⓒ 2017 EOFLOW CO., LTD. All Rights Reserved.
